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I. INTRODUCTION

[1]
"For the cure." This statement resonates throughout society and
offers a simple reasoning for the conduct of biomedical research. It
provides a strong impetus for advocates of biomedical research to pursue
appropriations to support research hypotheses, advanced medical
technologies, and targeted therapeutic strategies. Answering sophisticated
medical questions, however, requires researchers and clinicians to have an
adequate supply of materials necessary to facilitate their research
endeavors. These materials-commonly referred to as biospecimensmay include frozen human embryos, tissue specimens, blood samples,
buccal swabs, or exhaled breath condensate, all of which may be collected
and stored in biobanks.1
[2]
The use of human embryos for research purposes generated
national attention on March 9, 2009, following the release of Executive
Order (E.O.) 13505, titled "Removing Barriers to Responsible Scientific
Research Involving Human Stem Cells."2 E.O. 13505 recognized that
1See Biobanking, COLLINS DICTIONARY,
http://www.collinsdictionary.com/dictionary/english/biobanking, archivedat
http://perma.cc/WQU4-Q5GD (last visited Oct. 9, 2015) (defining biobanking as "the
practice of creating large-scale repositories of human biological material (e.g. blood,
urine, tissue samples, DNA, etc.) designed to further medical research").
1
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research involving human embryonic stem cells (hESCs) may have the
potential to increase the understanding of and improve treatments for
disabling diseases and conditions. Further, the E.O. removed the
limitations on federal funding for stem cell research to facilitate scientific
. .
.4
inquiry for new discoveries and therapies.
[3]
Following the release of E.O. 13505, the National Institutes of
Health (NIH) published guidelines for implementing it.5 The National
Institutes of Health Guidelines on Human Stem Cell Research indicate that
informed consent may need to be obtained for research involving hESCs
per 45 C.F.R. pt. 46. 6 The NIH Guidelines also outline specific
requirements of the informed consent process for donors of human
embryos for research purposes. Since the implementation of E.O. 13505,
the NIH has funded more than $577 million in hESC research. 8 In
addition, 351 hESC lines have been created and are included in the NIH
stem cell registry for research purposes.9

2 See
3

Exec. Order No. 13,505, 3 C.F.R. 229 (Mar. 9, 2009) [hereinafter Executive Order].

See id.

' See id.
See NationalInstitutes ofHealth Guidelines on Human Stem Cell Research, NAT'L
http://stemcells.nih.gov/policy/pages/2009guidelines.aspx, archivedat
http://perma.cc/2YQF-5SWZ (last modified Apr. 12, 2015) [hereinafter NIH Guidelines].
5

INST. OF HEALTH

6

See id.

7

See id.

See NIH Fundingfor Embryonic & Non-Embryonic Stem Cells, OATH OF GOD
http://www.oathofgodministries.com/nih-funding-for-embryonic-nonembryonic-stem-cells/, archivedat http://penna.cc/V9D3 -MWU6 (last visited Oct. 9,
2015).
MINISTRIES,

2
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[4]
While the scientific interest in-and federal funding for-research
using hESCs has increased, the use of human embryos and other
biospecimens for stem cell research and unforeseen future research has
been the subject of debate. This debate stems from inquiries regarding
how to best protect an individual's autonomy without impeding research
aimed at finding "the cure" for complex diseases. The majority of
commentaries proposing strategies to protect an individual's autonomy
reflect a similar underlying principle: improving informed consent.
[5]
Over the years, there have been several strategies proposed to
improve the informed consent process related to the use of
biospecimens-including donated human embryos-for unforeseen future
research. These strategies include proposed modifications to federal and
state regulations, 10 identifying consent models with applicability to
unforeseen future research," and altering the language of consent forms
given to research participants to facilitate an informed decision about
participation in research studies.12 In addition, these strategies aim to
prevent stigmatization, while also seeking to promote an individual's
autonomy by affording an increased control over the use of their
13
biospecimens.
Concerns of stigmatization reflect the notion that genomic
data generated from an individual's biospecimens may result in a person
or group of persons being stigmatized if their genetic makeup is linked to
9 See NIH Human Embryonic Stem Cell Registry, NAT'L INST. OF HEALTH,

http://grants.nih.gov/stem cells/registry/current.htm, archivedat http://perma.cc/XE54ANBQ (last visited Oct. 9, 2015).
10 See Christian M. Simon et al., Active Choice but Not Too Active: Public Perspectives
on Biobank ConsentModels, 13 GENETICS IN MED. 821, 821 (2011).

11 See Timothy Caulfield et al., Research Ethics Recommendationsfor Whole-Genome
Research: Consensus Statement, 6 PLOS BIOLOGY 430, 431 (2008).
12

See Simon et al., supra note 11, at 829.

1

See Caulfield et al., supra note, at 434.

Richmond Journal of Law & Technology

Volume XXII, Issue I

stigmatized diseases or research. 14
[6]
Recognizing that informed consent is a central tenet to conducting
research with human subjects,15 the Department of Health and Human
Services (HHS) issued its first national regulations in 1974 governing the
protection of human subjects in the research it supported. 16 In 1991, 14
additional federal departments and agencies adopted the rules set forth by
HHS.17 This "Common Rule" requires investigators supported by federal
funds to obtain and document the informed consent of individuals-or
their legally authorized representative-prior to participating in research. 18
However, the regulations comprising the Common Rule were developed
four decades ago and-although they have been amended-have not kept
pace with the increased sophistication of advanced scientific
methodologies and technologies. 19
[7]
In July 2011, HHS released an Advanced Notice of Proposed
Rulemaking (ANPRM), titled "Human Subjects Research Protections:
Enhancing Protections for Research Subjects and Reducing Burden,
Delay, and Ambiguity for Investigators," which proposed to modify the
See M. Dechdnes et al., Human Genetic Research, DNA Banking and Consent: A
Question of Form '?, CLINICAL GENETICS 221, 227 (2001).
14

15 See 2 TRIALS OF WAR CRIMINALS BEFORE THE NUREMBERG MILITARY TRIBUNALS
UNDER CONTROL COUNCIL LAW No. 10 181 (1949)
16 See Human Subjects Research Protections: EnhancingProtectionsfor Research
Subjects and Reducing Burden, Delay, and Ambiguity for Investigators, 76 Fed. Reg.
44,512, 44,512 (July 26, 2011) [hereinafter ANPRM].
17

See id.

s See id. at 44,517 (for the remainder of this paper, the term individual will encompass
the use of the term legally authorized representative as it relates to obtaining informed
consent).
19

See id. at 44,512.

4
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rules governing research involving human subjects. 20 Included in the
proposed modifications is a requirement that an individual give written
consent for the use of their collected biospecimens for unforeseen future
research. 2 1 However, such consent need not be study-specific, and can be
construed as a blanket consent allowing the individual's biospecimens to
be used in open-ended, unforeseen future research.2 2 Further, the broad
consent form proposed in the ANPRM would include check-off boxes for
special categories of research (e.g., creating a cell line, or reproductive
research) given the unique concerns these categories may raise to the
23
public, such as stigmatization. This differs from the Common Rule
where research using existing biospecimens can be conducted without
consent from the donor as long as the biospecimens do not include any
identifiable information.2 4
Although proposing the implementation of a broad consent model
[8]
for the unforeseen future research use of biospecimens, the identification
of special categories of research creates a broad-tiered hybrid model of
informed consent. This model-attempting to balance an individual's
autonomy while facilitating biomedical research-hinders advances in
research by facilitating stigmatization due to the identification of special
categories of research. Rather than encouraging an individual's autonomy,
the proposed broad-tiered hybrid model discourages donors from
consenting to the use of their biospecimens for stigmatized conditions due
to imperfect or insufficient information. Likewise, the proposed broadtiered hybrid model facilitates stigmatization by decreasing the number of
studies and investigators addressing stigmatized conditions due to the
20

See id.

21

See 76 Fed. Reg. 44,512, 44,515 (July 26, 2011).

22

See id.

23

See id. at 44,520.

24

See 45 C.F.R. § 46. 101(b)(4) (2012).

5
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paucity of heterogeneous biospecimens available. In response to the
ANPRM, this article proposes a modified broad consent model that creates
sustained interaction between donors and biobanking facilities by allowing
facilities to recontact donors for the future use of their biospecimens in
unforeseen and potentially stigmatizing research. Demonstrating its
applicability in reproductive medical research, this model strikes an
appropriate balance between an individual's autonomy and advancements
in biomedical research by providing the donor sufficient information to
make an informed decision without excess administrative burden on
researchers.
A.
Biobanking and Reproductive Medicine:
Preservation or Donation and Innovation?

Continued

[9]
A biobank refers to a stored collection of genetic samples that can
be linked with medical, genealogical, or lifestyle information from
specific population(s) which is gathered using a process of generalized
consent.2 5 Although all biobanks fall under this definition, they differ in
their functionality as related to biomedical research. A biobank may
collect their own specimens and data in order to conduct research or rely
on researchers at multiple sites to perform biospecimen collections and
subsequently serve a role in aggregating the biospecimens for future
research use. 26 Further, some biobanks-including the Coriell
27
Personalized Medicine Collaborative 2
serve a dual purpose in that they
25 See SECRETARY'S ADVISORY COMM. ON GENETICS, HEALTH, AND SOC'Y,
POLICY
ISSUES ASSOCIATED WITH UNDERTAKING A NEW LARGE U.S. POPULATION COHORT
STUDY OF GENES, ENVIRONMENT, AND DISEASE 16 (2007).

Susan M. Wolf et al., ManagingResearch Results andIncidental Findingsin Genomic
Research Involving Biobanks & Archived Datasets, 14 GENETICS IN MED. 361, 363
(2012).
26

27 See CPMC FA Qs, CORIELL PERSONALIZED MEDICINE COLLABORATIVE,
https://cpmc.coriell.org/about-the-cpmc-study/cpmc-faqs, archivedat
https://perma.cc/W233-KU4J (last visited Oct. 5, 2015).

6
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conduct their own research while also aggregating and distributing data to
investigators throughout the world.2 8
[10] Biobanks are a critical "resource for basic, epidemiological, and
transnational research"29 -including genome-wide association studies
which facilitate the identification of genetic markers of disease. 30
According to the National Bioethics Advisory Commission, an estimated
282 million human biospecimens 3 1 were being stored in the United States
as of 1998. Further, facilities accumulated stored biospecimens at a rate of
20 million cases per year. 32 Biobanks are diverse in the types of
biospecimens stored (e.g., breast or brain tissue) and in the types of
diseases they target (e.g., cancer or mental illness).3 3 Given the number
and diversity of samples stored, biobanks are a valuable resource to
researchers focused on understanding the etiology of a particular disease
and identifying novel strategies to prevent, diagnose, and treat diseases
and their associated co-morbidities.
[11]

As technology and our understanding of human biology have

See William McGeveran et al., Deidentificationand Reidentification in Returning
IndividualFindingsfrom Biobank and Secondary Research: Regulatory Challenges and
Models for Management, 13 MINN. J. L. SCI. & TECH. 485, 488 (2012).
28

Laura M. Beskow & Elizabeth Dean, Informed Consentfor Biorepositories:Assessing
ProspectiveParticipants'Understandingand Opinions, 17 CANCER EPIDEMIOLOGY
BIOMARKERS & PREVENTION 1440, 1440 (2008) [hereinafter Beskow & Dean].
29

See, e.g., Stephen J. O'Brien, Stewardship ofHuman Biospecimens, DNA, Genotype,
and ClinicalData in the GWAS Era, 10 ANN. REV OF GENOMICS AND HUM. GENETICS
193, 193 (2009).
30

31 See NAT'L BIOETHICS ADVISORY COMM'N, RESEARCH INVOLVING
HUMAN
BIOLOGICAL MATERIALS: ETHICAL ISSUES AND POLICY GUIDANCE 13 (1999).
32

See id.

See Kimberly J. Cogdell, Saving the Leftovers: Modelsfor Banking CordBlood Stem
Cells, 39 U. Mem. L. Rev. 229, 234 (2009) (citing Lori B Andrews, Harnessingthe
Benefits ofBiobanks, 33 J.L. MED. & ETHICS 22, 23 (2005)).
33

7
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matured, so has the use of biobanks. One area of scientific and
technological development that has benefited from biobanking is
reproductive medicine, as it relates to procreation via assisted reproductive
technologies (ART). The processes of in vitro fertilization (IVF) include
"ovulation induction, egg retrieval, fertilization, and embryo transfer." 34
From the first recorded attempt of IVF, 35 to the first IVF birth from
cryogenically frozen embryos, the successful use of ARTs in facilitating
procreation has increased as the technology has become more refined.3 6
IVF is an intricate process that can be both physically and mentally taxing
for women. To protect women's health and family welfare, "[t]he current
procedure of extracting and fertilizing multiple eggs" reduces "the number
of times [women] may need to undergo the procedure." 3 7
[12] As the processes and procedures of IVF have become more
refined, the number of cryogenically frozen embryos has increased. 38
Since the late 1970s, there have been nearly 400,000 embryos that have
been frozen and stored. 3 9 Of these, only 2.8% have been designated by
patients for use in research. 40 Research using hESCs derived from frozen
Emilie W. Clemmens, CreatingHuman Embryos for Research: A Scientist's
Perspectiveon Managingthe Legal and Ethical Issues, 2 Ind. Health L. Rev. 95, 96
(2005).
34

See Maggie Davis, Indefinite Freeze?: The Obligationsa CryopreservationBank Has
to AbandonedFrozen Embryos in the Wake of the Maryland Stem Cell Research Act of
2006, 15 J. HEALTH CARE L. & POL'Y 379, 382 (2012).
35

See id. at 383 (citing Margie Mietling Eget, The Solomon Decision: A Study ofDavis v.
Davis, 42 MERCERL. REv. 1113, 1115 (1991)).
36

37

See Clemmens, supra note 34, at 97.

38

See Davis, supra note 35, at 383.

39

See id. at 379.

40

See id.

8
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human embryos has gained significant interest over the past 15 years, as
researchers predict that hESCs may be used to treat various disease
conditions and to better understand the biological processes underlying
reproductive and regenerative medicine. 4 1 The use of hESCs in medical
research became increasingly important following the release of E.O.
13505, which permits embryos remaining after infertility treatment to be
used in creating hESC lines.4 2 Given the ability to use federal funding to
support hESC research, it is anticipated that the number hESC lines will
-43
increase.
[13]
As there is increased interest by investigators in working with
hESCs, it is reasonable to conclude that there will be a need for an
increased supply of frozen human embryos to derive hESCs for research.
As data indicate that the "vast majority of stored embryos" are "held for
family building," 4 4 the question arises as to where investigators requiring
frozen human embryos for research can acquire them. This question
underlies the conundrum that exists with respect to the disposition of
frozen human embryos following family completion. This quandary
includes the question of whether frozen human embryos should be
preserved indefinitely due to abandonment, discarded, 4 or donated for
research.4 6
See Ethics Comm. of the Am. Soc'y for Reproductive Med., DonatingEmbryos for
Human Embryonic Stem Cell (hESC) Research: A Committee Opinion, 100 FERTILITY
STERILITY. 935, 935 (2013) [hereinafter ASRM Ethics Comm.].

&

41

42

Id. at 936.

43

See id.

44

DAVID HOFFMAN ET AL.,

How MANY

FROZEN HUMAN EMBRYOS ARE AVAILABLE FOR

RESEARCH? (2003).

A.D. Lyerly et al., Decisional Conflict and the Disposition ofFrozen Embryos:
Implicationsfor Informed Consent, 26 HuM. REPROD. 646, 646 (2011).

9
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[14]
Legal scholars suggest that indefinitely freezing embryosspecifically those that have been abandoned 4 7 -is both impractical and
immoral. 48 They argue that the lack of a definitive disposition for
abandoned embryos may result in crysopreservation banks incurring
financial costs as a result of preserving the embryos. 4 9 Facilities will likely
shift these costs onto persons undergoing IVF, in order to defray the costs
incurred by storing abandoned embryos.o In addition to concerns about
practicality, indefinitely freezing abandoned embryos may be considered
morally reprehensible 1 and result in litigation.52
[15]
Whether an embryo should be discarded poses a significant
problem for cryopreservation banks faced with determining if an embryo
should be indefinitely stored. To bring uniformity to embryo disposition,
legal scholars suggest imposing a statutorily defined period, forcing
couples to make a choice about the disposition of their embryos or be
Donation of human embryos to couples seeking fertility treatment is beyond the scope
of this paper and will not be addressed.
46

See Davis, supra note 35, at 380 n. 11 (defining an abandoned embryo as a
'cryogenically stored human embryo whose progenitors have fallen out of contact with
the cryopreservation storage facility without a forwarding address or directive to either
dispose or donate the embryos.") (citing Paul C. Redman II & Lauren Fielder Redman,
4

Seeking a Better Solution for the Disposition ofFrozen Embryos: Is Embryo Adoption the
Answer?, 35 TULSA L.J. 583, 583-84 (2000)).
48

See id. at 396.

4

See id.

50

See id. at 396-97.

See id. at 397 (citing I. Glenn Cohen, The Right Not To Be a Genetic Parent?, 81 S.
Cal. L. Rev. 1115, 1186 (2008) (discussing the Catholic belief that it is "a sin to destroy
or indefinitely freeze preembryos").
51

52

See Davis, supra note 35, at 397 (citing Doe v. Obama, 631 F.3d 157, 164 (4th Cir.

2011)).

10
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subject to a predetermined outcome.
The American Society for
Reproductive Medicine (ASRM) suggests that ART programs develop
program-specific policies focused on the disposition of embryos.
However, in the absence of program-specific policies, ASRM proffers that
it is ethically acceptable to consider embryos abandoned if there are no
written instructions from the couple regarding disposition, diligent efforts
have been made to contact the couple, and it has been at least 5 years since
contact has been made.54
[16] In addition to the options of indefinitely freezing or discarding,
frozen and/or abandoned embryos may be donated for research purposes.
This option has been met with divergent views. Legal scholars suggest that
abandoned frozen human embryos be donated for research, as donation
supplies research facilities with the embryos needed without having to
create them for the sole purpose of research. 5 Doing so would also
alleviate the burden of having more couples affirmatively consent to have
their unused and/or unwanted embryos donated for research.56 In contrast,
the ASRM contends that abandoned embryos should not be used for
research unless the patient(s) had previously given consent. 7 Guidance
from the ASRM indicates that abandoned embryos should be used for
hESC research only if patient(s) were informed of the possibility that their
embryos may be used for hESC research and provided their consent to
53

See id. at 398.
See Amato, P; Brzyski et al., Disposition ofAbandoned Embryos: A Committee
FERTILITY & STERILITY 1848, 1849 (2013).

Opinion, 99

See Davis, supra note 35, at 381 (citing Natalie R. Walz, AbandonedFrozen Embryos
and Embryonic Stem Cell Research: Should There Be A Connection?, 1 U. ST. THOMAS
J.L. & PUB. POL'Y 122, 124 (2007) (suggesting that abandoned frozen embryos be made
available for embryonic stem cell research)).
56

See id. at 149-52.
See ASRM Ethics Comm., supra note 41, at 938.

11
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h58
such use.
[17]
The perspective of ART patients is critical to determining an
appropriate disposition for frozen human embryos. Evidence suggests that
patients' undergo considerable stress in attempting to make a decision,
resulting in the inclination to perpetually freeze the embryo. 9 For
example, McMahon and colleagues found that approximately 70% of
patients with embryos delayed their decision regarding disposition for up
to 5 years.60 Data also demonstrate that approximately 40% of patients
having completed childbearing were unable to determine a preferred
disposition of their excess embryos. 6 1
[18]
In addition to these data, recent evidence from Lyerly and
colleagues provides further insight into the decisional conflict underlying
62
the disposition of frozen human embryos.
In a survey of 1,005
individuals with cryopreserved embryos, 8 1. 3 % indicated that at the time
of freezing they had specific intentions as to the disposition of their
embryos.6 3 Regarding the individuals' current intentions, 14.6% indicated
that they were very/somewhat likely to keep their embryos frozen forever
with 49.9% indicating that they were very/somewhat likely to donate their

58

See id.

See Sheryl de Lacey, ParentIdentity and 'Virtual' Children: Why PatientsDiscard
Rather than Donate Unused Embryos, 20 HuM REPROD. 1661, 1661 (2000).
59

See Catherine McMahon et al., Mothers Conceiving Through In Vitro Fertilization:
Siblings, Setbacks, andEmbryo DilemmasAfter Five Years, 10 REPROD TECH 131, 134
(2000).
60

See Anne Lyerly et al., FertilityPatients'Views About Frozen Embryo Disposition:
Results of a Multi-institutionalU.S. Survey, 93 FERTILITY & STERILITY 499, 506(2010).
61

62

See Lyerly, supra note 45, 646.

63

See id. at 651.
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frozen embryos for research. 64 In assessing the underlying cause of
fertility patients' views regarding frozen embryo donation, data indicate
that 47.8% of patients believed that they did not have enough information
regarding what happens to embryos donated for research. 65 Taken
together, these data highlight the necessity of an informed consent process
that adequately addresses patients' needs regarding donation and future
research uses of frozen human embryos.
B. Human Subjects Research Protection
[19]
Federal regulations governing research involving human
subjects 6 6 -including
those underlying informed consent-are based
primarily on recommendations from the National Commission for the
Protection of Human Subjects in Biomedical and Behavioral Research.6 7
Originally implemented by HHS, these regulations have since been
adopted by 14 other federal departments and agencies as a Common
Rule. 6 8 The Common Rule applies to all human subjects' research that is
conducted, supported, or subject to regulation by any federal department
or agency which takes appropriate administrative action to make the
policy applicable to such research.6 9
64

See id.

65

See id. at 652.

66

See, e.g., 45 C.F.R.

§ 46.101 (2014).

67 See Marshall B. Kapp, A Legal Approach to the Use ofHuman BiologicalMaterials
for Research Purposes, 10 RUTGERS J. L. & PUB. POL'Y 1, 5 (2013); see also NAT'L
COMM'N FOR THE PROT. OF HUMAN SUBJECTS OF BIOMEDICAL & BEHAVIORAL

RESEARCH, DEP'T OF HEALTH, EDUC., & WELFARE, THE BELMONT REPORT: ETHICAL
PRINCIPLES FOR THE PROTECTION OF HUMAN SUBJECTS OF RESEARCH,

http://www.hhs.gov/ohrp/humansubjects/guidance/belmont.html, archived at
http://perma.cc/58DP-GWRY (April 18, 1979) [hereinafter BELMONT REPORT].
68

See 76 Fed. Reg. 44,512, 44,512 (July 26, 2011).

13
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[20]
Federal regulations define a human subject as "a living individual
about whom an investigator (whether professional or student) conducting
research obtains (1) [d]ata through intervention or interaction with the
individual, or (2) [i]dentifiable private information."7 0 The Common Rule
requires investigators supported by federal funds to obtain and document
the informed consent of individuals or their legally authorized
representative prior to participating in research protocols.
[21]
Investigators seeking informed consent should only do so under
circumstances providing an individual a sufficient opportunity to consider
whether they should participate in the study. 72 Informed consent
documents and procedures should be in language understandable to the
individual, and should not include any exculpatory language requiring an
individual to waive any of their legal rights or releases the investigator,
45 C.F.R. § 46.101(a) (2014). Research is defined as "a systematic investigation,
including research development, testing and evaluation, designed to develop or contribute
to generalizable knowledge." Id. at § 46.102(d).
6See

Id. at § 46.102(f) (defining "intervention" as including "both physical procedures by
which data are gathered (for example, venipuncture) and manipulations of the subject or
the subject's environment that are performed for research purposes;" identifying
"interaction" as including "communication or interpersonal contact between investigator
and subject;" and defining "private information" as "information about behavior that
occurs in a context in which an individual can reasonably expect that no observation or
recording is taking place, and information which has been provided for specific purposes
by an individual and which the individual can reasonably expect will not be made public
(for example, a medical record). Private information must be individually identifiable
(i.e., the identity of the subject is or may readily be ascertained by the investigator or
associated with the information) in order for obtaining the information to constitute
research involving human subjects.").
7o

71 See id. at § 46.102(c) (defining "legally authorized representative" as "an individual or
judicial or other body authorized under applicable law to consent on behalf of a

prospective subject to the subject's participation in the procedure(s) involved in the
research.").
72

See id. at § 46.116.
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.

sponsor, institution, or its agents from liability for negligence. 3 Further,
the possibility of coercion or undue influence to the individual should be
- - - 74
minimized
[22]
The Common Rule sets forth basic elements that investigators
must include when seeking participation in a research study. Basic
elements of informed consent include a statement indicating that the study
involves research, an explanation of the purposes of the research, the
expected duration of participation, a description of the procedures to be
followed, and identification of any experimental procedures. Further, the
individual must be provided a description of any reasonably foreseeable
risks 76 and/or benefits 7 7 associated with the study and a disclosure of any
alternative procedures or alternative treatments that may be advantageous
to the individual. Individuals must also be provided a description of how
confidentiality will be maintained 7 9 and an explanation of whom to contact
for questions about the research, the individual's rights, and researchrelated injuries.8 0 With respect to research-related injuries, individuals
must also be provided information as to whether compensation or any
medical treatments are available if injury occurs. 8 1 Informed consent
73

See 45 C.F.R. § 46.116 (2014).

7

See id.
See id. at § 46.116(a)(1).

76

See id. at § 46.116(a)(2).
See id. at § 46.116(a)(3).
See 45 C.F.R. § 46.116(a)(4) (2014).

79

See id. at § 46.116(a)(5).

oSee id. at

46.116(a)(7).

See id. at § 46.116(a)(6).
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documents must also include a statement that an individual's participation
is voluntary, that they may withdrawal participation at any time, and that
refusal to participate or withdrawal will not result in any loss of benefits or
-82
penalties.
[23]
Central to research involving human subjects is the requirement
that research protocols undergo Institutional Review Board (IRB) review
and receive IRB approval. 8 3 IRBs are empowered to review, approve,
See id. at § 46.116(a)(8); see also id. at § 46.116(b)(1)-(6) (citing additional elements
of informed consent that shall be provided to individuals or their representatives, when
appropriate: "(1) A statement that the particular treatment or procedure may involve risks
to the subject (or to the embryo or fetus, if the subject is or may become pregnant) which
are currently unforeseeable; (2) Anticipated circumstances under which the subject's
participation may be terminated by the investigator without regard to the subject's
consent; (3) Any additional costs to the subject that may result from participation in the
research; (4) The consequences of a subject's decision to withdraw from the research and
procedures for orderly termination of participation by the subject; (5) A statement that
significant new findings developed during the course of the research which may relate to
the subject's willingness to continue participation will be provided to the subject; and (6)
The approximate number of subjects involved in the study.").
82

See 45 C.F.R. § 46.111 (2014) (identifying the criteria necessary for IRB approval: "(a)
In order to approve research covered by this policy the IRB shall determine that all of the
following requirements are satisfied: (1) Risks to subjects are minimized: (i) By using
procedures which are consistent with sound research design and which do not
unnecessarily expose subjects to risk, and (ii) whenever appropriate, by using procedures
already being performed on the subjects for diagnostic or treatment purposes. (2) Risks to
subjects are reasonable in relation to anticipated benefits, if any, to subjects, and the
importance of the knowledge that may reasonably be expected to result. In evaluating
risks and benefits, the IRB should consider only those risks and benefits that may result
from the research (as distinguished from risks and benefits of therapies subjects would
receive even if not participating in the research). The IRB should not consider possible
long-range effects of applying knowledge gained in the research (for example, the
possible effects of the research on public policy) as among those research risks that fall
within the purview of its responsibility. (3) Selection of subjects is equitable. In making
this assessment the IRB should take into account the purposes of the research and the
setting in which the research will be conducted and should be particularly cognizant of
the special problems of research involving vulnerable populations, such as children,
83
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disprove, and-if necessary-require modification of a research protocol
to secure approval. 8 4 Included in the IRB approval process of human
subjects research is a review of the research protocol, including consent
documents required for participant inclusion.85 With respect to informed
consent, an IRB is to assess and determine whether the information
provided to an individual complies with the regulations governing
informed consent. 86 "An IRB may waive the requirement for the
investigator to obtain a signed consent ... if ... the research presents no
more than minimal risk"87 or the only record linking the individual and
research is the consent document, which may pose the potential risk and
harm of a breach of confidentiality.8 8 Following approval, the research
protocol is then subject to continuing IRB oversight and formal review at
least annually. 89 However, there is a concern as how to strike an
prisoners, pregnant women, mentally disabled persons, or economically or educationally
disadvantaged persons. (4) Informed consent will be sought from each prospective
subject or the subject's legally authorized representative, in accordance with, and to the
extent required by §46.116. (5) Informed consent will be appropriately documented, in
accordance with, and to the extent required by §46.117. (6) When appropriate, the
research plan makes adequate provision for monitoring the data collected to ensure the
safety of subjects. (7) When appropriate, there are adequate provisions to protect the
privacy of subjects and to maintain the confidentiality of data. (b) When some or all of
the subjects are likely to be vulnerable to coercion or undue influence, such as children,
prisoners, pregnant women, mentally disabled persons, or economically or educationally
disadvantaged persons, additional safeguards have been included in the study to protect
the rights and welfare of these subjects.").
4See id. at

46.109(a).

See id. at

§ 46.109(b).

86

See id.
See id. at

§ 46.117(c)(2).

See 45 C.F.R. § 46.117(c)(1) (2014).
89

See id. at

§ 46.109(e).
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appropriate balance to ensure that individuals are informed of all the
potential uses of their biospecimens without impeding biomedical research
by creating administrative burden.
C. Applicability of the Common Rule to the Unforeseen
Future Use of Biospecimens
[24] The Common Rule is applicable to the collection, storage, and use
of frozen human embryos and other biospecimens, albeit in finite
circumstances. Research involving biospecimens "obtained prospectively
from living people . . . falls within the definition of human subjects

research [as] it involves an 'intervention or interaction with' a living
individual." 90 Guidance from the HHS Office for Human Research
Protections (OHRP) further clarifies what constitutes human subjects
research as it pertains to biospecimens. 91 OHRP indicates that "obtaining
identifiable private information or identifiable specimens for research
purposes constitutes human subjects research." 9 2 "Obtaining identifiable
private information or identifiable specimens includes . . . but is not
limited to . . . [the] us[e], stud[y], or analy[sis] for research purposes [of]
identifiable private information or identifiable specimens . . . provided to
investigators from any source . . . [including those] that were already in

the possession of the investigator." 93 This includes research using human
Leslie E. Wolf, Advancing Research on Stored BiologicalMaterials:Reconciling Law,
Ethics, and Practice, 11 MINN. J.L. Sc & TECH. 99, 130 (2010) (quoting 45 C.F.R. §
46.102(f) (2014)).
90

91 See OFFICE FOR HUMAN RESEARCH PROTS., U.S. DEP'T OF HEALTH & HUMAN SERVS.,
GUIDANCE ON RESEARCH INVOLVING CODED PRIVATE INFORMATION OR BIOLOGICAL

SPECIMENS 1, http://www.hhs.gov/ohrp/policy/cdebiol.html, archived at
http://perma.cc/VZ3 C-5K8D (Oct. 16, 2008) [hereinafter OHRP BIOLOGICAL SPECIMENS
GUIDANCE].
92

Id. at 3-4 (emphasis omitted).

93

Id. at 4 (emphasis omitted).
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cell lines (e.g., hESCs) where the donor may be identified due to coding
that retains identifiable information. 94
[25] However, "private information [and] specimens [are] not
[considered] to be individually identifiable when they cannot be linked to
specific individuals by the investigator(s) either directly or indirectly
through coding systems." 95 Research involving coded 96 human
biospecimens therefore does not constitute human subjects research if the
biospecimens "were not collected specifically for the currently proposed
research project through an interaction or intervention with living
individuals." 97 Additionally, for research involving coded human
biospecimens to not be considered human subjects research, "the
investigator(s) cannot [be able to] readily ascertain the identity of the
individual(s) to whom the coded private information or specimens
pertain." 98 Thus, in vitro research or in vivo animal research using hESCs
retaining a link to identifiable information ordinarily would not be
considered human subjects research if the investigator was unable to

94 See OFFICE FOR HUMAN RESEARCH PROTS., U.S. DEP'T OF HEALTH & HUMAN SERVS.,
GUIDANCE FOR INVESTIGATORS AND INSTITUTIONAL REVIEW BOARDS REGARDING
RESEARCH INVOLVING HUMAN EMBRYONIC STEM CELLS, GERM CELLS AND STEM CELLDERIVED TEST ARTICLES 3, http://www.hhs.gov/ohrp/policy/stemcell.pdf, archived at
http://perma.cc/2NJN-NDMJ (Mar. 19, 2002) [hereinafter OHRP STEM CELL GUIDANCE].
95 OHRP BIOLOGICAL SPECIMENS GUIDANCE, supra note 91, at 4.

Under the OHRP guidance, "coded" is defined as "1. identifying information (such as
name or social security number) that would enable the investigator to readily ascertain
the identity of the individual to whom the private information or specimens pertain has
been replaced with a number, letter, symbol, or combination thereof (i.e., the code); and
1. a key to decipher the code exists, enabling linkage of the identifying information to the
private information or specimens." Id. at 3.
96

97

Id. at 4.

98

Id. at 4.
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access identifiable private information related to the cell line.99
[26] Biobanks facilitate the ability to obtain and share coded
biospecimens for research without the need for informed consent via
several mechanisms. For example, an investigator may enter into an
agreement with the "key holder" of coded biospecimens which prohibits
the release of coded information to the investigator until the individual is
deceased. 100 This type of agreement is characterized as the honest broker
concept. 101 In this role, the honest broker (biobank) collects and provides
health information to researchers in such a manner that it is not reasonably
possible for the researchers to identify the subjects. 102 The applicability of
the honest broker concept as it relates to biospecimens and human subjects
research has been further characterized by legal scholars. Here, an
investigator may share previously collected biospecimens with one or
multiple investigators. 103 As the subsequent investigator(s) did not obtain
the biospecimens via interaction or intervention with the donors andbased on an agreement-does not and cannot receive personally
identifiable information, the research would not be considered human
subjects research or require informed consent. 104
[27] In addition to the honest broker methodology, there may also be
IRB-approved written policies and procedures for a biobank that prohibits
99

See OHRP STEM CELL GUIDANCE, supra note 94, at 3.

100 See OHRP BIOLOGICAL

SPECIMENS GUIDANCE, supra note

91, at 7.

101 See Rajiv Dhir, et al., A MultidisciplinaryApproach to Honest Broker Servicesfor
Tissue Banks and ClinicalData:A Pragmaticand PracticalModel, 113 CANCER 1705,
1707 (2008).

102 See id.
103 See Wolf, supra note 90, at 131.
104 See id.
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the release of the key to the investigators under any circumstances, until
the individuals are deceased. 105 Such schemata refer to centralized
biobanks that store biospecimens and assume the responsibility of
ensuring that biospecimens are distributed and used in accordance with
human subjects research regulations. 1 0 6 This approach is similar to the
honest broker approach as there are agreements in place prohibiting the
release of identifiable information. 10 7 However, the agreements protecting
the identifiable information apply to any investigator seeking to use the
biospecimens as opposed to being negotiated on an ad hoc basis. 108
[28]
Research using existing biospecimens may also be exempt from
federal regulation if the biospecimens are publicly available, or if the
information is recorded in such a manner that subjects cannot be
identified-directly or indirectly-via linked subject identifiers. 109
D. Modifying the Common Rule to Regulate the Use of
Biospecimens in Unforeseen Future Research
[29]
In July 2011, HHS released an ANPRM entitled "Human Subjects
Research Protections: Enhancing Protections for Research Subjects and
Reducing Burden, Delay, and Ambiguity for Investigators." 110 The
ANPRM proposes to modify the rules governing research involving
human subjects." The ANPRM indicates that the "current regulations

1os

See OHRP BIOLOGICAL SPECIMENS GUIDANCE, supra note 91, at 4.

106

See id.; see also Wolf, supra note 90, at 131.

107

See Wolf, supra note 90, at 131.

108 See id.
109

See 45 C.F.R. § 46.10 1(b)(4) (2014).

110

76 Fed. Reg. 44,512, 44,512 (July 26, 2011).
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governing human subjects research were developed years ago" and "have
not kept pace with the evolving human research enterprise," including "the
proliferation of multi-site clinical trials and . . . research involving . .
biological specimen repositories." 1 12 The ANPRM recognizes
biospecimens and data . . . collected for clinical use or
purposes other than for the proposed research are often an
important source of information and material for
investigators, and the reuse of existing data and materials
can be an efficient mechanism for conducting research
without presenting additional physical or psychological
risks to the individual .... 113

Citing the Institute of Medicine, the ANPRM notes the importance of
"'facilitat[ing] important health research by maximizing the usefulness of
patient data associated with biospecimens banks . . . thereby allowing
novel hypotheses to be tested with1 14 existing data and materials as
knowledge and technology improve.'"
[30]
While recognizing the importance of research involving
biospecimens, the ANPRM proposes to enhance human subjects
protections by requiring written consent for biospecimens collected for
purposes other than the currently proposed research.1 15 In an effort to
increase protections by modifying consent requirements, the ANPRM
...
See id.
11

2

id.

113

Id. at 44,523-24.

114

Id. at 44,524 (quoting

NAT'L ACAD. OF

SCIs.,

BEYOND THE HIPAA PRIVACY RULE:

ENHANCING PRIVACY, IMPROVING HEALTH THROUGH RESEARCH 10

eds. 2009)).
115

See 76 Fed. Reg. 44,512, 44,519 (July 26, 2011).
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suggests investigators use and human subjects consent be obtained via a
brief standard consent form. 116 The brief standard consent form would
allow human subjects to agree to "permit future research" and "be broad
enough to cover all biospecimens to be collected related to a particular set
of encounters with an institution (e.g. hospitalization) or even to any
biospecimens to be collected at any time by that institution." 11 7 Thus,
"[t]he general rule would be that a person needs to give consent, in
writing, for research use of their biospecimens, though that consent need
not be study-specific, and could cover open-ended future research." 118
Although not study-specific, the "standardized general consent form
would permit the subject to say no to all future research" and would have
"check-off boxes" to allow the subject to determine the types of research
that may be performed with their biospecimens, including but not limited
to creating cell lines or reproductive research. 119
[31] In addition to proposing the adoption of a brief, standardized
consent form to cover unforeseen future research using a subject's
biospecimens, the ANPRM also proposes that consent forms be improved.
According to the ANPRM, federal regulations will facilitate the
development of improved consent forms by "prescribing appropriate
content that must be included in consent forms, with greater specificity ...
[and] restricting content that would be inappropriateto include." 120 The
ANPRM also notes that improving consent forms would also require
"limiting the acceptable length of various sections of a consent form; ...
prescribing how information should be presented . .. reducing institutional
'boilerplate' [language] . . . and . . . making available standardized
116

See id.

1 17

Id. at 44,515.

118

Id.

119 Id. at 44,519-20.
120

76 Fed. Reg. 44,512, 44,523 (July 26, 2011).
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Thus, the overall goal is to have broad,
standardized consent forms (with special categories of research) that are
streamlined-in both length and content-in order to facilitate the subject
making an informed decision about the future use of their biospecimens.
Prior to implementing rules requiring informed consent modifications, it is
critical to assess the current models of obtaining informed consent and the
attitudes of perspective research participants related to those models.
Likewise, it is essential to determine whether modifying the rules
governing informed consent would hinder research due to stigmatization.
12 1

II. INFORMED CONSENT IN UNFORESEEN FUTURE RESEARCH

[32] Informed consent is the hallmark of medical decision-making as
related to the practice of medicine and the conduct biomedical research.
Critical to the doctrine of informed consent is the ethical principle of
respect for persons or autonomy. Pursuant to the Belmont Report, there
are two ethical convictions underlying respect for persons: 1) "individuals
should be treated as autonomous agents," and 2) those "with diminished
autonomy are entitled to protection." 122 In order to respect autonomy, it is
essential to give credence to an autonomous person's considered opinions
and choices and to avoid obstructing their actions unless they are
detrimental to the wellbeing of others. 123 Thus, repudiation of an
autonomous person's considered judgments, withholding information
necessary to make such judgments, or denying their freedom to act upon
such judgments offends their autonomy.124
[33]
12

1

In the context of human subjects research, respecting autonomy

id.

122 BELMONT REPORT, supra note 67.
123

See id.

124

See id.
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requires that human subjects are provided adequate information and that
their participation is voluntary. 125 Autonomy takes on two distinct forms
with regard to research involving biospecimens. In the first form, a human
subject may consent to the collection and storage of their biospecimens
and their use in a primary research study. 12 6 Thus, an individual may
provide consent for the storage and use of cancerous tissue following
excision in a primary research study assessing for biomarkers underlying
the tissue's proliferative nature.
[34] In the second form, there is the difficult challenge of how to obtain
informed consent for the use of an individual's biospecimens for
unforeseen future research. 127 Scholars maintain that permission for use of
biospecimens for unforeseen research may be considered valid only if the
individual has been informed of the possibility of their use. 128 Notifying
human subjects of the possibility that their biospecimens may be used in
unforeseen future research is a rather simple task that may be satisfied
with a blanket statement in a consent form. Although simple in the
abstract, the adequacy of such an approach may be challenged as it does
not divulge the potential uses of the biospecimens-including the benefits
and risks-to allow an individual to make an informed decision.
[35] With respect to affording an individual the opportunity to make an
informed decision, the quandary is how to protect autonomy given the
difficulty-if not impossibility-of predicting all of the potential future
125

See id.

See Amy L. McGuire & Laura M. Beskow, Informed Consent in Genomics and
Genetic Research, 11 ANN. REV. GENOMICS AND HUM. GENETICS 361, 361-81 (2010)
[hereinafter McGuire & Beskow].
126

127

See id.

128 See Henry T. Greely, Breaking the Stalemate: A ProspectiveRegulatory Framework
for Unforeseen Research Uses ofHuman Tissue Samples and Health Information, 34
WAKE FOREST L. REV. 737, 754 (1999).
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research uses of an individual's biospecimens. Such a prediction is
impractical, given the ever-changing developments in technology and
scientific methodologies that may elucidate therapeutic targets for
diseases. Technological and scientific innovations will further result in an
insurmountable number of research questions and hypotheses that are
impossible to predict. Additionally, consent forms including the use of
biospecimens for unforeseen future research would require investigators to
predict all of the potential future risks and benefits associated with such
research in order to allow human subjects to make an informed decision
about future use. To strike a balance between human subjects autonomy
related to the use of their biospecimens in unforeseen future research and
efficiency in biomedical research, three consent models applicable to
biobanking have been proposed: broad consent, tiered consent, and studyspecific consent.
A. Broad Consent for Unforeseen Future Research
[36] Broad consent requests that human subjects prospectively agree
that their biospecimens may be used in appropriate unforeseen future
research as determined by a biobank and/or related oversight body. 12 9
Researchers, ethicists, and legal scholars have argued that broad consent is
inadequate and inapposite to the Common Rule as it does not inform
individuals of what the unforeseen future research will entail or its
potential risks and benefits. 130 For example, Arnason contends that the
broader that consent is "the less informed it becomes[,] [and] [i]t is
129 See Christian Simon et al., Active Choice but Not Too Active: PublicPerspectives on
Biobank ConsentModels, 13 GENET. MED. 821, 821-31(Lippincott, Williams & Wikins
eds., 2011).
130 See id. (citing David E. Winickoff & Richard N. Winickoff, The CharitableTrust as a
Modelfor Genomic Biobanks, 349 NEW ENG. J. OF MED. 1180, 1180-84 (2003));
Timothy Caulfield et al., Research Ethics Recommendationsfor Whole-Genome
Research: Consensus Statement, 6 PLOS BIOLOGY 430, 430-35 (2008); Mylkne
Deschines et al., Human Genetic Research, DNA Banking and Consent: A Question of
'Form '?, 59 CLINICAL. GENET. 221, 224 (2001).
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misleading to use the notion of informed consent for participation in
research that is unforeseen and has not been specified in a research
protocol." 1 3 1 Individuals providing broad consent for the use of their
biospecimens in unforeseen future research therefore are considered to be
giving their permissionl32 as opposed to their informed consent as the
research uses of their biospecimens cannot be described in detail.
[37]
Despite these concerns, the World Health Organization (WHO)
recommended investigators use blanket informed consent forms (broad
consent) to facilitate their research. 1 3 3 Here, the WHO recognized blanket
informed consent-allowing for future use of biospecimens in unspecified
projects-as the most efficient and economical approach as it avoids the
necessity for and costs associated with recontacting individuals before
each new research project. 1 3 4 Likewise, the United Nations Educational,
Scientific and Cultural Organization International Bioethics Committee
concluded that a "system which required fresh consent would be
extremely cumbersome and could seriously inhibit research and it is for
this reason that a system of 'blanket consent' covering all forms of future
medical research might be preferable. . . .,,135 Although broad consent may
131 Vilhjalmur Arnason, Coding and Consent: Moral Challenges of the DatabaseProject
in Iceland, 18 BIOETHICS 27, 42 (2004).
132

See Greely, supra note 128, at 752-54.

133 WORLD HEALTH ORGANIZATION, PROPOSED INTERNATIONAL GUIDELINES ON
ETHICAL
ISSUES IN MEDICAL GENETICS AND GENETIC SERVICES (1998),

http://whqlibdoc.who.int/hq/1998/WHOHGNGLETH_98.1.pdf,
http://perma.cc/4VM5-Y7QF.
134

archived at

See id. at 13.

135 UNITED NATIONS EDUC., SCI. AND CULTURAL ORG., HUMAN GENETIC DATA:
PRELIMINARY STUDY BY THE IBC ON ITS COLLECTION, PROCESSING, STORAGE AND USE

1, 16 (2002),
http://portal.unesco.org/shs/en/files/2138/10563744931Rapfinalgendata
gendata en.pdf, archivedat http://perma.cc/84E4-DRKE.
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be more efficient for researchers with respect to the cost, quality, and
quantity of future research, the question remains whether broad consent
adequately protects human subjects' autonomy.
B. Tiered Consent for Unforeseen Future Research
[38] An alternative to broad consent is tiered or categorical consent.
Presented at the time of the initial consent to participate in a biobank and
future research, tiered consent allows human subjects to choose from a list
of diseases (e.g., cardiovascular, cancer, developmental) or research
capabilities (e.g., genomics, proteomics, hESC) in which their samples
may be used in the future.136 Using a tiered consent model, human subjects
may also be afforded alternative options related to their biospecimens.
These options may include consenting to whether their biospecimens can
be shared among researchers, used for commercial purposes, used in an
identifiable manner, and/or limited for the purposes of only conducting the
primary study. 137 Scholars maintain that appropriate implementation of the
tiered consent model requires that consent forms provide a maximum
number of options (i.e., disease states, research methodologies) that are
empirically informed and indicative of an individual's informational needs
and preferred level of control over their biospecimens. 138 Doing so is
considered to both respect and enhance autonomy by allowing human
subjects to exert control over whether, how, with whom, and how much of
their biospecimens are shared. 139

136

See McGuire & Beskow, supra note 126.

137 See Leslie E. Wolf & Bernard Lo, UntappedPotential:IRB Guidancefor the Ethical
Research Use ofStored BiologicalMaterials, 26 IRB: ETHICS & HUMAN RESEARCH 1, 4

(2004).

&

138 See Susanne B. Haga & Laura M. Beskow Ethical, Legal, and SocialImplications of
Biobanksfor Genetics Research, 60 ADV. GENET. 505, 520 (2008) [hereinafter Haga
Beskow].
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[39] Tiered consent has been criticized, however, due to the burdens it
places on researchers. 140 Such burdens include (1) the need for biobanks to
track and match research participants approved uses of their biospecimens
with the research being proposed or performed, 14 1 (2) increased research
costs, 14 2 and (3) delayed progress in elucidating and understanding the role

of specific genes, proteins, and/or molecular mechanisms in co-morbid
conditions due to the compartmentalization of research by individual
diseases. 143 Thus, similar to the broad consent model, the challenge in
implementing a tiered consent model is in striking an appropriate balance
that respects an individual's autonomy without impeding biomedical
research by overburdening a researcher.
C. Study-Specific Consent for Unforeseen Future Research
[40]
Study-specific consent differs from broad and tiered consent
models in that biobank participants are recontacted, provided information
about the current study in which they are eligible to participate in, and
asked to participate.144 In doing so, study-specific consent is similar to
informed consent obtained for a primary study as it provides individuals
See Amy L. McGuire & Richard A. Gibbs, Currents in ContemporaryEthics: Meeting
the Growing Demands of Genetic Research, 34 J. LAW. MED. ETHICS 809, 811 (2006).
139

See Haga & Beskow, supra note 138 (citing William Grizzle et al., Recommended
Policiesfor Uses ofHuman Tissue in Research, Education, and Quality Control, 123
140

ARCH. PATHOL. LAB. MED. 296, 299 (1999)).

See Darren Shickle, The ConsentProblem Within DNA Biobanks, 37 STUD. HIST.
PHILOS. BIOL. BIOMED. SCI. 503, 516 (2006).
141

142 See David Wendler, One-time General Consent for Research on Biological Samples,
332 BRIT. MED. J. 544 (2006).

&

143 See Mark A. Rothstein, Expanding the EthicalAnalysis ofBiobanks, 33 J.L. MED.
ETHICS 89, 92 (2005).
144

See ANPRM, supra note 16, at 44,524.
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with detailed information about the current study, including the risks and
benefits associated with participation. 14 However, study-specific consent
has been considered impractical as related to unforeseen future research
with biospecimens, due to the costs and logistical roadblocks associated
with recontacting potential research participants.1 46
D. Human Subjects Perspectives Regarding Consent for
Unforeseen Future Research
[41] In determining the type of consent model that strikes an
appropriate balance between an individual's autonomy related to the
unforeseen future use of their biospecimens without impeding biomedical
research, it is critical to consider the perspectives of human subjects.
There have been several empirical studies assessing human subjects'
willingness to participate in research, the unforeseen use of their
biospecimens in research, and their expectations regarding consent.
[42] In 2006, the NIH Department of Clinical Bioethics performed
meta-analyses assessing patient willingness and preference with respect to
consent for research using their biospecimens.1 47 The NIH collected and
subsequently reviewed data from 30 studies-consisting of more than
33,000 people-assessing the views of research participants, patients,
families, religious leaders, and the general public. 14 8 Data revealed that
respondents wanted to decide whether their biospecimens can be used for
research purposes. 149Additionally, of the 30 studies included in the metaanalysis, 20 studies investigated the willingness of individuals to donate
145

See Simon, supra note 129, at 822.

146

See ANPRM, supra note 16, at 44,524.

147

See Wendler, supra note 142, at 544-47.

141

See id. at 544.

149

See id.
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their biospecimens. 150 Of these 20 studies, 17 provided evidence
demonstrating that approximately 80% of respondents would donate their
biospecimens if asked.15 1 The majority of respondents who were unwilling
to donate were concerned with the methodologies used to obtain
biospecimens as opposed to the possibility of the future use of the
biospecimens for research purposes.152 Regarding consent preferences, the
NIH assessed data from six studies which revealed that 7 9 -9 5% of
respondents were willing to provide a one-time general (broad) consent for
the use of their biospecimens in research. 153
[43] Although criticized due to the lack of heterogeneity in the
populations assessed, subsequent studies support the findings of the
NIH. 154 Beskow and Dean identified that 85% of potential research
participants "would allow their blood and information to be stored,
indefinitely . . . for use in future research."15 5 Additionally, data from
Simon and colleagues assessing public perspectives on broad, tiered, and
study-specific consent revealed that broad consent garnished the strongest
support from potential biobank participants. 156 Participants in the study
recognized that implementation of a broad consent model would result in
them having less control over the use of their biospecimens. However,
150

See id.

1 See D.Wendell, supra note 142, at 544.
152

See id. at 544-45.

153

See id. at 546.

154 See Laura M. Beskow & Elizabeth Dean, Informed Consentfor Biorepositories:
Assessing Prospective Participants'Understandingand Opinions, 17 CANCER
EPIDEMIOL BIOMARKERS 1440, 1447 (2008).
15 5

Id. at 1446.

156

See Simon, supra note 129, at 9.
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the participants believed that broad consent-in addition to being less
costly and less burdensome for the participants-may result in "a larger
and more diverse collection of samples and thus provide researchers with
'a broad amount of people of different backgrounds and . . . more to
choose from."' 158 Empirical research therefore suggests that human
subjects prefer to exert some level of control over whether their
biospecimens can be used in unforeseen future research, with the majority
of indicating that a broad consent model adequately addresses that
preference.15 9

E. Stigmatization and the Use of Biospecimens for Unforeseen
Future Research
[44] Researchers, ethicists, and legal scholars have argued that
informed consent, by protecting research participants' autonomy aids in
preventing stigmatization. Stigma refers to a mark setting a person apart
from others and links the marked person to characteristics that are
undesirable. 160 Further, when a person or group of persons are linked to an
undesirable characteristic, "rejection and isolation" of the stigmatized
person or persons comes into play. 161 Therefore, stigma is a matter of
degree and is contingent upon the strength or weakness with which a
marked person can be linked to undesirable characteristics. 162
151

See id.

158

id.

159

See Id. at 13; see also ANPRM, supra note 16, at 44,524.

160 See Bruce G. Link et al., On Stigma and Its Consequences: Evidencefrom a
LongitudinalStudy ofMen with DualDiagnoses ofMental Illness and Substance Abuse,
38 J. OF HEALTH & SOC. BEHAV. 177, 179 (1997).
16

1

162

id.
See id.
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[45]
Stigmatization has commonly been associated with mental health
disorders1 6 3 (e.g., depression and addiction), human immunodeficiency
virus (HIV), 164 and reproductive health. 165 Individuals therefore are
concerned that their biospecimens may be used for unforeseen future
research on stigmatized disorders or that they may be identified as
someone with a predisposition to or undergoing treatment for a
stigmatized disease.166 Although some scholars maintain that public fear
of discrimination is unwarranted due to a lack of reported cases of genetic
discrimination,16 7 this argument underscores the impact of stigmatization,
which is distinct from discrimination. For example, with respect to HIV,
stigma may affect decisions related to testing and seeking treatment for
physical and psychological needs. 168 Additionally, couples capable of
transmitting deleterious genes to their offspring may be deterred from
considering ARTs.169
[46]
Given the data that can be extracted from the use of an individual's
biospecimens and the inherent risk of being associated with a stigmatized
disease, there is growing concern regarding the unforeseen future use of
163 See Bruce G. Link, A Modified Labeling Theory Approach in the Area ofMental
Disorders:An EmpiricalAssessment, 54 AM. SOC. REV. 400, 401 (1989).

Ronald Bayer, Stigma and the Ethics ofPublic Health: Not Can We but Should We, 67
SOC. SCI. AND MED. 463, 464-66 (2008).
164

165

Rebecca J. Cook & Bernard M. Dickens, Reducing the Stigma in Reproductive Health,

125 INT'L J. OF GYNECOLOGY AND OBSTETRICS 89, 89-92 (2014).

See Lori B. Andrews, Harnessingthe Benefits ofBiobanks, 33 JL. MED. & ETHIcS 2,
4 (2005).
166

167 See Henry Greely, Genotype Discrimination:The Complex Casefor Some Legislative
Protection, 149 U. PA. L. REv. 1483, 1489-90 (2001).
168

See Bayer, supra note 164, at 464.

169

See Cook & Dickens, supra note 165, at 91.
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biospecimens. An additional concern is that providing individuals with the
opportunity to opt-out of studies focused on stigmatized conditions will
impede research aimed at identifying the underlying causes of and
treatments for these conditions.
F. Consent under the ANPRM: Striking an Appropriate
Balance?
[47] As previously described, the ANPRM seeks to modify the rules
governing informed consent as related to research involving human
subjects. 170 The ANPRM recommends that human subjects provide their
written consent indicating that their collected biospecimens can be used
for unforeseen future research.17 1 The ANPRM envisions the use of a
broad, standardized consent form that will facilitate the use of
biospecimens in open-ended future research as opposed to being studyspecific. 172 Although not study-specific, the broad standardized consent
form would have check-off boxes for special categories of research that an
individual may not want to participate in "given the unique concerns they
might raise for a significant segment of the public...."173
[48] As written, the ANPRM interconnects the concepts of broad and
tiered consent, as it affords individuals the opportunity to consent to all
unforeseen future research with their biospecimens and to refuse having
their biospecimens used for special categories of research. Although
attempting to strike an appropriate balance for the unforeseen future use of
biospecimens by protecting human subjects' autonomy without impeding
biomedical research, the ANPRM is imperfect in that the consent model
170

See ANPRM, supra note 16, at 44,512.

171

See id. at 44,519.

172

See id.

173

Id. at 44,519-20.
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proposed facilitates stigmatization. The allowance of special categories
facilitates the stigmatization of medical conditions that individuals are
hesitant-if not reluctant-to provide consent for. Thus, implementation
of the consent model proposed will impede biomedical research by (1)
discouraging individuals from consenting to the use of their biospecimens
for conditions identified as special categories, (2) decreasing studies
seeking to characterize and identify treatments for stigmatized conditions,
and (3) decreasing the number of investigators addressing stigmatized
conditions.
[49]
By identifying special categories of research in which individuals
may want to refrain from, the proposed consent modifications are further
stigmatizing conditions that certain members of the public may find
objectionable. In doing so, it is reasonable to suggest that individuals may
have a tendency to automatically decline consenting to research related to
those special categories. Such a decision may be based upon imperfect or
insufficient information in that an individual may believe that the federal
government
has
conducted
extensive,
well-controlled,
and
demographically diverse studies to determine individuals' perspectives on
what categories of research they find objectionable. 174 Likewise, an
individual may suspect that the federal government has conducted
analyses balancing the potential risks and benefits associated with the
special categories of research and therefore decline to have their
biospecimens used for research aligned with the special categories.
[50]
Implementation of federal regulations requiring consent forms to
identify special categories of research that a potential participant may find
objectionable would be detrimental to the underlying purpose of the
ANPRM, which is to improve individuals' autonomy. By identifying
special categories of research, consent would not be informed by a
disclosure of information related to the research that may be conducted or
of its risks or benefits. Rather, individuals would be influenced by the
174

It is unclear at this time how the federal government intends to determine whether

research on a specific disease state should be classified as a special category.
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federal government's identification that research befitting of special
category designation may not be in their best interests to participate in.
The ANPRM's consent model therefore may be construed as coercive in
that the federal government's opinion as to what constitutes a special
category would influence a person's decision to having their biospecimens
used in unforeseen future research designated as special.
[51] Biomedical research focused on the identified special categories
may also be impeded if the scope of the special categories is overly broad.
If overly broad, the special categories would preclude individuals from
allowing their biospecimens to be used for any research that would fall
within that designated special category. For example, if reproductive
medicine was used as a special category, an individual would be unable to
designate that they would not want their frozen human embryos used for
creating a cell line as opposed to assessing developmental disorders or
understanding predispositions to infertility. Thus, research in these areas
would be impeded due to the breadth of the reproductive medicine special
category.
[52] Additionally, if the special categories are overly broad, the ability
to conduct correlative studies-which may identify the role of a specific
gene, protein, or molecular mechanism in multiple and pathologically
diverse conditions-may be impeded. Investigators seeking to understand
whether there is a genetic correlate to chemotherapy induced infertility
would be precluded from using any biospecimens of cancer patients that
did not consent to their specimens being used for reproductive medicine
research. Thus, by decreasing research participation in special categories
the proposed consent model would decrease autonomy by hindering an
individual's informed decision, further the stigmas associated with the
identified special categories, and impede scientific advances to
understand, treat, and ultimately de-stigmatize these conditions.
17 See, Julie A. Burger, What is Owed Participantsin Biotechnology Research?, 84 CHI.KENT L. REV. 55, 70 (2009).
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[53]
As previously noted, identification of special categories will hinder
biomedical innovation for stigmatized conditions classified as special by
increasing the reluctance to consent to the use of biospecimens for future
research. Thus, implementation of an interconnected broad-tiered consent
model using special categories would decrease the number of
biospecimens available for unforeseen future research. A lack of
biospecimens would also impede biomedical research as investigators
would not have an adequate and diverse supply of samples to use in
addressing their research hypotheses. Due to a limited sample supply,
investigators may choose to modify their research hypotheses addressing
special categories. Alternatively, investigators may direct their efforts
towards answering questions based on the availability of samples they can
obtain (e.g., cancer-related diseases) as there will be a more robust sample
population in which to conduct both small and large scale studies.
[54]
The identification of special categories of research also changes
the federal government's functionality from a regulatory body providing
oversight for research involving human subjects to an advocacy
organization. Here, the federal government is advocating that research
focused on one type of disease (e.g., cancer) should evoke robust
participation whereas research focused on special categories of disease
(e.g., reproductive medicine) should not. As such, the implementation of
an interconnected broad-tiered consent model that identifies special
categories of research allows the federal government to dictate innovation
by identifying which fields of research are most important and where
resources should be directed.
III. PROPOSED CONSENT MODEL: BROAD CONSENT WITH THE OPTION
To BE RECONTACTED

[55]
In determining whether there is a consent model that adequately
addresses the concerns of research participants and investigators, the
answer is seemingly "it depends." As noted above, the broad-tiered hybrid
consent model proposed in the ANPRM would deter consent for future
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research efforts in special categories. A consent model applicable to both
respecting participant autonomy and facilitating medical research is one
where an individual provides blanket consent to future unforeseen
research with the option to be recontacted for specific categories of
research.
[56]
This proposed consent model protects an individual's autonomy by
allowing them to make an informed choice about whether to participate in
special categories of research. The participant's choice is informed by
having the option to be recontacted if the use of their biospecimens would
be integral to a particular area of research. The recontact option ensures
that an individual is making an informed choice by understanding the
specifics of the special category based studies their specimens would be
used for. The option to be recontacted for special categories of research
therefore provides for a sustained interaction to be developed with a
biospecimen donor.
[57]
To assess the utility of the broad consent model with the option to
be recontacted (BCORED), this author provides an overview of how its
implementation may be applicable in the context of reproductive
medicine. As noted above, since the release of E.O. 13505176 and its
implementation by the NIH,1 7 7 federal funding and scientific inquiry using
hESC lines has increased. However, indecision by prospective donors as
to the disposition of their frozen human embryos continues in part due to a
lack of clear processes for making an informed decision. 178
[58]
Here, we envision a continuous consent process for the donation of
human embryos for research purposes. The consent process would be
176

See Executive Order, supra note 2.

177

See NIH Guidelines, supra note 5.

See Tasha Kalista et al., Donation ofEmbryos For Human Development, 8 CELL STEM
CELL 360 (2011).
17s
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initiated annually as prospective donors are given disposition options for
their embryos included with their annual storage bill from their IVF clinic
or storage facility.17 9 The timing of seeking informed consent is critical in
the context of reproductive medicine. It is important that prospective
donors make the decision to donate after deciding to no longer store their
embryos. so Doing so protects the donors from undue influence or pressure
to donate from overzealous clinicians, researchers, and institutions.
Further, it ensures that donations are made without any potential
misconceptions about restrictions or benefits of care depending on the
donor's disposition decision.1 82
[59]
If interested in donating their embryos for research, donors would
receive an informed consent packet. The informed consent packet must be
consistent with federal regulations governing human subjects research and
NIH guidelines regarding research with human embryos. The informed
consent packet will be broad in that it allows the donor to consent to all
unforeseen future research that their donated embryos may be used for.
However, to be consistent with NIH and ASRM guidance consent forms
would also include categories of research-including stigmatized research
categories-that the embryos may be used for. These categories may
include reproductive medicine-such as early human development,
embryo quality, and improving IVF clinical outcomes-or the production
of cell lines for research purposes. Included in the informed consent
packet would also be information on the right of the donor to withdraw
from the research. Following NIH guidelines, donors would be informed
that they retain the right to withdraw consent to donate their embryo(s)
until the time that the embryos were used to drive hESCs or until
179

See id.

1so See ASRM Ethics Comm., supra note 41, at 935.
1Ild. at 938; see also NIH Guidelines, supra note 5.
182

See NIH Guidelines, supra note 5.
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information linking the identity of the donor with the embryo was no
longer retained.1 83
[60]
Contact information for biobank coordinators would also be
included in the informed consent packet. The central function of the
biobank coordinators would be to discuss the current research projects that
the embryos may be used for, confirm an individual's understanding of the
differences in the research categories, and confirm their intent to donate. 184
Following confirmation of the consent to donate, the biobank coordinators
would also work with the donor's IVF clinic or storage facility to transfer
embryos.1 85
[61]
Although this structure of informed consent is similar to the broadtiered consent hybrid model proposed in the ANPRM, the consent model
noted above is caveated in that it would also allow for donors to be
recontacted. Recontact permits research related issues-such as future
study-to be discussed with individuals on an ongoing basis. 186
Developing a sustained interaction with individuals is critical to ensuring
that they are making an informed decision about the use of their donated
embryos and/or other biospecimens, specifically for research on
stigmatized conditions. The ability of donors to make an informed
decision under this framework will be facilitated by their sustained
interaction with the biobank coordinators who can provide more detailed
information (e.g., for stigmatized research) about the ongoing uses about
their embryos.

183

See id.

1s1

See Kalista, supra note 178, at 360-61.

1 5

See id. at 361.

1

186 Justin Lowenthal et al., Specimen Collectionfor InducedPluripotentStem Cell
Research: Harmonizingthe Approach to Informed Consent, 1 STEM CELLS
TRANSLATIONAL MED. 409, 414 (2012).
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[62]
Protecting individual's autonomy without impeding the progress of
biomedical research is essential to any informed consent model.
Implementation of the BCORED model assists with this goal, especially
as it relates to research on stigmatized diseases. As noted above, the
broad-tiered consent hybrid model proposed in the ANPRM facilitates
stigmatization by allowing an individual to opt-out of any and all special
categories of research that their biospecimens may be used for. As an
alternative, the BCORED model proposed herein may increase the
willingness of individuals to have their biospecimens used for stigmatized
conditions. Here, a donor has a better understanding of how and why their
embryos or biospecimens will be used due to the sustained interaction
with the biobank coordinator.
[63]
The sustained interaction gained from the BCORED model both
increases communication to inform donors about the research they will be
contributing to and creates openness within the research enterprise. 187
Such openness may assist in increasing donor willingness to participate in
research they may have objected to previously due to imperfect or
insufficient information. Increases in participation are also likely to attract
investigators to study stigmatized conditions due to the increase in the
number of samples available to address specific research hypotheses and
conduct correlative studies. Thus, the BCORED model would increase
autonomy by supporting a donor's informed decision, increase research
participation for stigmatized conditions, and facilitate investigations on
stigmatized conditions due to a more robust sampling of biospecimens in
which to test research hypotheses.
[64]
Importantly, the BCORED model is consistent with empirical
research studies focused on potential donors' perspectives. Empirical
research suggests that donors would prefer to exert some level of control
over whether their biospecimens can be used in unforeseen future
research, with the majority indicating that a broad consent model
See Rosario Isasi et al., SustainedInteraction: The New Normalfor Stem Cell
Repositories?,6 REGEN. MED. 783, 783 (2011).
1s?
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adequately addresses that preference. However, the option to be
recontacted assists in overcoming a significant challenge to informed
consent related to embryo disposition: that a potential donor's attitude
about their embryos changes overtime.1 88 By allowing for the option to be
recontacted, donors are able to make an informed decision about which
additional studies-if any-to participate in upon recontact, a decision
which may have changed overtime.
[65]
This author acknowledges that his recommendations for
implementation of a consent model that allows donors to be recontacted to
support a sustained interaction have previously met criticism. Although
recontacting donors has been considered impractical under a studyspecific consent model due to the costs and logistical roadblocks
associated with recontact, 189 the BCORED model may help quash those
concerns. The BCORED consent model uses biobank coordinators to
maintain the sustained interaction with donors. The biobank coordinators
would be responsible for recontacting donors, explaining details of the
research, obtaining informed consent and withdrawal requests, and
answering any questions or concerns that donors may have. As these tasks
do not align with the duties of the investigator, there is no impediment to
his or her research due to administrative burden.
[66]
Likewise, implementation of the BCORED model does not
substantially increase research costs. Research costs under the BCORED
model are mitigated by the use of a biobank coordinator. Salary support
for the biobank coordinator would be paid by the biobank at no additional
cost to the investigator. The investigator would only be required to pay for
s See Lyerly, supra note 45, at 650 (citing Robert Nachtigall et al., How Couples Who
Have Undergone in Vitro FertilizationDecide What To Do with Surplus Frozen
Embryos, 92 FERTIL. STERIL. 2094-96 (2009)); CR Newtown et al., Changes in Patient
Preferencesin the Disposal of CryopreservedEmbryos, 22 HuM. REPROD. 3124,25
(2007).

See ANPRM, supra note 16 at 44,524.
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the use of the biobank (i.e., to obtain informed consent and acquire
biospecimens) which would be documented in their federally funded grant
or contract. Even if the biobank requires salary support for biobank
coordinators to be supplemented by the investigators, direct research costs
would not be substantially impacted as the use of biobank coordinators
would obviate the need for on-site research coordinators to obtain
informed consent or recontact prospective donors.
IV. CONCLUSION

[67] Informed consent is central to the conduct of biomedical research
involving human subjects. It is critical that potential research participants
be presented with sufficient information to make an informed decision
about whether to participate in both primary and unforeseen future
research studies. However, there is a concern as how to appropriately
balance an individual's autonomy as related to the unforeseen future use
of their biospecimens with the advances in biomedical research.
Implementation of the BCORED model improves upon the current federal
regulations governing informed consent in that it allows individuals to
give broad consent to any and all research or to be recontacted to discuss
specific categories of research that may be stigmatizing. In doing so, the
BCORED model ensures that an individual's autonomy is protected by
affording the opportunity to make an informed decision about the future
use of their biospecimens. Likewise, the BCORED model does not impede
biomedical research as it uses a third party intermediary for recontact and
may result in a more robust, heterogeneous sample of biospecimens to find
"the cure" for diseases, including those that routinely elicit stigmatization.
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